A new biotech company has been launched with the goal of taking on one of the world’s rarest neurodegenerative…
To continue reading please go to the article on The Pharma Letter
Updated: Dec 16, 2021
A new biotech company has been launched with the goal of taking on one of the world’s rarest neurodegenerative…
To continue reading please go to the article on The Pharma Letter
Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr
SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst